Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 0326-12-RMB | Other Identifier | Rambam Health Care Campus, Haifa, Israel |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
In our previous study, NCT01631695, we proposed and clinically evaluated the Medasense pain response index, PRI, in anesthetized patients undergoing surgery. Note: the name PRI has been changed to NoL (Nociception Level) Index.
The PRI is based on a non-linear combination of several pain-related physiological parameters into a one unique index (0-100).
In this study we aim to validate the performance of the PRI by:
investigating the patient's PRI response to surgical painful stimuli under different levels of analgesia:
investigating the effect of beta-blockers on PRI performance in patients taking chronic beta-blocker treatment.
The study is based on recording and analyzing the subject's physiological signals, while recording painful events, medication dosing and different clinical signs.
Pain is an unpleasant sensation, ranging from slight discomfort to intense suffering. Since pain is a subjective phenomenon, it has frequently defied objective, quantitative measurements. Today, in order to measure pain, subjective uni-dimensional scales are used to quantify pain. One of the most common scale used to rate a patient's pain intensity is the Numeric Pain Scale (NPS), usually scored from 0 to 100. Hitherto, those scales are based on the subjective evaluation of pain by the patient.
During anesthesia the patient cannot communicate and therefore the verbal or other report is impossible. As a consequence, due to misrepresentation of the existence or extent of pain, care providers may fail to estimate the correct measure of pain and give too much or too little medication, leading to possible complications and adverse reactions. A validated scoring system of subject's pain level, or as in the case of an anaesthetised patient, subject's nociception level, is therefore needed.
In this study the investigators intend to test and analyze the performances of Medasense pain response index, PRI, by comparing it with other standard pain related indicators (Heart Rate (HR), Heart Rate Variability (HRV), Skin Conductance, etc) before and after painful stimuli at different levels of analgesia. In addition, in order to reduce the variability between stimuli, a standardized stimulus (Tetanic ,30 sec, 100Hz, 60mA) will be given to all patients after sleep induction and before intubation, with and without administration of Fentanyl and the values of the PRI during these stimuli will be investigated.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Low opioid level | Active Comparator | Base level of remifentanil effect side concentration: 2ng/ml Stopped recruitment (May 2014) |
|
| High opioid level | Active Comparator | Base level of remifentanil effect side concentration: 4ng/ml Stopped recruitment (May 2014) |
|
| chronic beta-blocker treatment | Other | Patients with chronic beta-blocker treatment prior to surgery and study. Will all be allocated to the high opioid level arm without randomization. Continue recruitment. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Base level of remifentanil effect side concentration: 2ng/ml | Drug | constant remifentanil level of 2ng/ml administered using Target Control Infusion pumps. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in Medasense's non-invasive pain monitoring index in response to painful events | outcome measure will be assessed one minute before painful event, and will be compared to a measure taken during the painful event. Note: during data analysis it became aparent that these definitions cannot be met. For example: the time of various clinical stimuli cannot be identified within seconds. Also, there is no meaning to a measure taken during event. Therefore, to avoid including part of the stimulus in the pre stimulus window, we restricted analysis to the first 30 seconds of the designated 1 minute before the event (-30 to -60 seconds). Similarly, the post stimulus window start was defined 10 seconds after the event annotation and the post stimulus window enlarged to 80 seconds. | at time of surgery. 1 minute before and 1 minute after painful stimuli (for instance: intubation, skin incision, trocar insertion) |
| Measure | Description | Time Frame |
|---|---|---|
| Change in all pain related physiological parameters (heart rate, heart rate variability, Plethysmograph amplitude, skin conductance, etc) in response to specific painful stimuli | Outcome measures will be assessed one minute before painful event, and will be compared to measures taken during the painful event. Note: same changes as in outcome 1 measure. | at time of surgery. 1 minute before and 1 minute after painful stimuli (for instance: intubation, skin incision, trocar insertion) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ruth Edry, MD | Rambam Health Care Campus | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Rambam Health Care Campus | Haifa | 31096 | Israel |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 22647429 | Background | Treister R, Kliger M, Zuckerman G, Aryeh IG, Eisenberg E. Differentiating between heat pain intensities: the combined effect of multiple autonomic parameters. Pain. 2012 Sep;153(9):1807-1814. doi: 10.1016/j.pain.2012.04.008. Epub 2012 May 29. | |
| 23835792 | Background | Ben-Israel N, Kliger M, Zuckerman G, Katz Y, Edry R. Monitoring the nociception level: a multi-parameter approach. J Clin Monit Comput. 2013 Dec;27(6):659-68. doi: 10.1007/s10877-013-9487-9. Epub 2013 Jul 9. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010146 | Pain |
| D000377 | Agnosia |
| ID | Term |
|---|---|
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D010468 | Perceptual Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077208 | Remifentanil |
| ID | Term |
|---|---|
| D011422 | Propionates |
| D000144 | Acids, Acyclic |
| D002264 | Carboxylic Acids |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Base level of remifentanil effect side concentration: 4ng/ml | Drug | constant remifentanil level of 4ng/ml administered using Target Control Infusion pumps. |
|
|
| chronic beta-blocker treatment | Other | Patients from the chronic beta-blocker treatment group will not be randomized, and will all be allocated to the high opioid level group. |
|
| Change in Medasense index/pain related physiological parameters/subjective pain assessment in response to changes in the level of analgesic drugs | Outcome measures will be assessed one minute before administration of analgesic drug, and will be compared to measures taken 5 minutes after. Note: after fentanyl administration - same change as in outcome 1 measure. | at time of surgery. 1 minute before and 5 minute after analgesics administration |
| D019954 | Neurobehavioral Manifestations |
| D009422 | Nervous System Diseases |
| D010880 |
| Piperidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |